<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-19_08-39-39</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Clear cell ovarian carcinoma, platinum-refractory with multifocal progression (pelvis, liver, bone) and severe anemia; immediate priorities are stabilizing organ function, clarifying performance status, and completing biomarker work-up to choose between limited-intensity non‑platinum therapy and best supportive care. [@2022-12-29|MR; @2022-12-29|CT; @20230103|2023-01-03; @pubmed:33758607]

Core Treatment Strategy:
- Urgently correct anemia and repeat full labs (CBC/diff, coagulation, renal, full liver panel) to reassess treatment fitness. [@20230103|2023-01-03]
- Document ECOG, pain, neurologic, GI/urinary symptoms, and prior toxicity to decide systemic therapy versus best supportive care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]
- Complete MSI, PD‑L1, TMB, updated tumor NGS including somatic ATM, then screen early for appropriate clinical trials. [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|15]
- If PS and organs permit, plan individualized non‑platinum systemic approach with concurrent early palliative care; otherwise prioritize best supportive care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]

Change Triggers:
- If ECOG ≥3 or organ dysfunction worsens, shift intent from systemic therapy consideration to symptom‑focused best supportive care only.
- If biomarkers or trials reveal actionable target/eligibility, pivot from empiric non‑platinum approach to biomarker‑driven/clinical‑trial strategy.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）术后白紫+卡铂化疗6程，末次：2022.8.172022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)MR（2022.07.17）：2022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)肿瘤标志物（2022.10.12）：CA19-9:77.20U/ml↑,CA125:89.60U/ml↑,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(绝经前)↑,ROMA.:36.67%(绝经后)↑。CT（2022.10.25）：肝内多发结节，部分较前新见，转移可能，请结合MR检查。另见肝囊肿同前。MR（2022.10.24）：盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。盆腔系膜多发强化小结节，转移可能。2022.11.10外院血常规：白细胞 2.36，红细胞 3.56，血红蛋白 97，血小板 153外院生化：ALP　105，NA 136，PAB 1242022.11.30外院血常规：白细胞 3.46，红细胞 3.48，血红蛋白 94，血小板 1342022.11.17外院肿瘤指标：CA125　403，Ca153　63.8，Ca199 96.8，Ca724 695肿瘤标志物（2022.12.29）：CA19-9:229.00U/ml↑,CA125:933.00U/ml↑,CA15-3:86.00U/ml↑,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/L↑,ROMA:41.02%(绝经前)↑,ROMA.:85.98%(绝经后)↑。MR（2022.12.30）：盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。右侧髂骨新见强化结节，转移可能。盆腔系膜多发强化小结节同前相仿，转移可能。直肠局部肠壁增厚伴强化。CT（2022.12.30）：肝内多发转移结节，较前增多，部分较前增大。另见肝囊肿同前。脾脏片状影，脾脏梗塞？随访。咨询报告</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6 cycles&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;白紫+卡铂&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian carcinoma with hepatic and pelvic metastatic disease&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;histology&quot;:&quot;首先考虑为透明细胞癌&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;卵巢癌复发&quot;,&quot;site&quot;:&quot;卵巢&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;白紫+卡铂&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml (2022-10-12)&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Debulking surgery + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;45.7&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;161&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;562&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-11-10&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;97&quot;},{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary debulking surgery&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of 白紫+卡铂&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising CA125&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;白紫+卡铂 (6 cycles)&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;(部分+)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;(少弱+)&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;(+/-)&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;(60%+)&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;(灶+)&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;(-)&quot;}],&quot;involvement_sites&quot;:[&quot;intestinal wall full thickness&quot;,&quot;peritoneum (left retroperitoneal tumor)&quot;,&quot;vagina (partial)&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7*4*2.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Molecular/genetic testing not reported&quot;,&quot;Definitive origin laterality not specified&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;sacrum&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Pelvis post-op changes&quot;,&quot;presacral mass, consider recurrence with adjacent sacral involvement&quot;,&quot;multiple enhancing small mesenteric nodules in pelvis, suggest metastases&quot;],&quot;impression&quot;:&quot;Recurrence with possible sacral involvement and pelvic mesenteric metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple hepatic nodules, some new compared to prior&quot;,&quot;hepatic cysts unchanged&quot;],&quot;impression&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;right iliac bone&quot;,&quot;sacrum&quot;,&quot;rectum&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral mass increased in range with heterogeneous enhancement&quot;,&quot;new enhancing nodule in right iliac bone&quot;,&quot;multiple pelvic mesenteric enhancing nodules&quot;,&quot;rectal local bowel wall thickening with enhancement&quot;],&quot;impression&quot;:&quot;Progressive pelvic recurrence with possible peritoneal and sacral involvement; new right iliac bone lesion&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;,&quot;spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size&quot;,&quot;patchy splenic shadow, possible splenic infarct&quot;],&quot;impression&quot;:&quot;Progressive hepatic metastases; splenic abnormality noted, follow-up suggested&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: Recurrent metastatic ovarian clear cell carcinoma after failure of first-line platinum chemotherapy fits a relapsed/metastatic gynecologic malignancy needing ≥2L systemic therapy.
- Missing eligibility confirmations (0-2 items):
  - Confirmation of other protocol-specific clinical/laboratory criteria (ECOG, organ function, etc.)
  - None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Please urgently reassess ECOG, symptoms, and repeat full labs including iron studies/transfusion threshold, as Hb 74 g/L may limit systemic options and requires immediate management. Also clarify if any prior maintenance or non-platinum therapy was given post-1L to avoid inadvertent retreatment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Given already evident multifocal progression on CT/MR, please advise whether PET-CT would realistically alter systemic versus purely palliative strategy, or can be deferred. Also confirm any suggestion of spinal canal/sacral neural compromise that would change urgency of local intervention.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before committing to non‑platinum systemic therapy, we need ECOG, full labs, and detailed prior toxicity to judge feasibility versus best supportive care only.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Please confirm MSI/MMR, PD‑L1 and, if possible, expand NGS to clarify the ATM variant and identify any actionable alterations for systemic options or trials.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Most recent CT/MR already document clear systemic progression (pelvis, liver, bone); additional PET‑CT is unlikely to change staging but may help if you’re considering focal local therapy or trial eligibility requiring metabolic documentation.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>From a pathology standpoint, current histology/IHC/molecular data are internally consistent; key missing elements are MSI, PD-L1, TMB, and updated NGS results to complete the biomarker profile for future decision-making.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Pathology confirms clear cell ovarian carcinoma with intact MMR and HRD-negative status; MSI, PD-L1, TMB, and updated tumor NGS (including somatic ATM characterization) remain outstanding and could refine biomarker-directed options.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Rapidly progressive, platinum‑resistant clear cell ovarian carcinoma with liver/bone metastases; prioritize non‑platinum systemic strategy and symptom‑directed palliation. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @pubmed:33758607]\n\n- Before firm regimen choice, urgently document ECOG status, pain/bleeding, GI/urinary function, and detailed organ function (full CBC, coagulation, renal).\n\n- Arrange comprehensive biomarker review/confirmation (MMR/MSI, PD‑L1, TMB if available; clarify ATM variant significance) and discuss clinical‑trial eligibility.&quot;,
  &quot;oncologist&quot;: &quot;- Early biochemical and radiologic recurrence ~2 months post-adjuvant suggests platinum-refractory clear cell ovarian carcinoma; consider non-platinum systemic strategy. [@pubmed:33758607]\n\n- Significant anemia (HGB 74 g/L) and hepatic metastases require assessment of performance status and organ function before intensive combination therapy. [@20230103|2023-01-03; @20221229|2022-12-29]\n\n- Missing: updated staging imaging report, ECOG status, detailed prior regimen toxicities, and confirmation of any prior/ongoing maintenance or local therapies.&quot;,
  &quot;radiologist&quot;: &quot;- Progressive pelvic presacral mass with sacral and possible peritoneal involvement; new right iliac bone lesion, suspicious for metastasis. [@2022-12-29|MR]\n\n- Hepatic metastases increased in number and size; stable hepatic cysts; new patchy splenic lesion concerning for infarct, needs follow‑up. [@2022-12-29|CT]\n\n- Disease demonstrates multifocal progression (pelvis, liver, bone), indicating systemic metastatic pattern requiring multidisciplinary management planning. [@pubmed:37901720]&quot;,
  &quot;pathologist&quot;: &quot;- Histology and IHC support ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not explicitly assigned.[@report_id|2022-03-28]\n\n- MMR proteins intact (MLH1/MSH2/MSH6/PMS2 positive); MSI status by molecular testing still unknown/needs update.[@report_id|2022-03-28]\n\n- Germline ATM p.Y316C reported with HRD negative; somatic panel otherwise non-actionable. Full tumor NGS (MSI/TMB, others) needs update.[@report_id:OH2203828|2022-04-18][@guideline:nccn_ovariancancer_v3_2025__v00000000|15]&quot;,
  &quot;nuclear&quot;: &quot;- No PET-CT available; metabolic assessment of pelvic, hepatic, splenic, sacral, and iliac lesions is unknown/needs update.  \n\n- Current staging and recurrence assessment rely on MR/CT showing progressive pelvic, hepatic, and bone metastases, but metabolic burden remains undefined [@2022-12-29|MR; @2022-12-29|CT].  \n\n- PET-CT could better distinguish active recurrence versus post-treatment change and clarify systemic metastatic extent, potentially altering stage and prognosis [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- First, urgently reassess ECOG, symptom burden, and repeat full labs (CBC, coagulation, renal, liver) to define treatment fitness. [@20230103|2023-01-03]\n\n- Proceed with comprehensive biomarker work‑up (MSI, PD‑L1, TMB, updated NGS including ATM clarification) to refine non‑platinum/clinical‑trial options. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15; @OH2203828|2022-04-18]\n\n- Plan non‑platinum systemic strategy versus best supportive care based on PS/organ function, integrating early palliative care; reserve PET‑CT for trial/local‑therapy decisions. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @2022-12-29|CT; @2022-12-29|MR]&quot;,
    &quot;oncologist&quot;: &quot;- Urgently correct anemia (HGB 74 g/L) and repeat full labs, documenting ECOG and symptom burden to define fitness. [@20230103|2023-01-03]  \n\n- Once status clarified, select individualized non‑platinum systemic versus best supportive approach, considering clear cell, platinum‑refractory recurrence. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @pubmed:33758607]  \n\n- Complete biomarker profile (MSI, PD‑L1, TMB, updated NGS/ATM) and reserve PET‑CT for potential local therapy or trial eligibility.&quot;,
    &quot;radiologist&quot;: &quot;- Imaging shows progressive multifocal metastases (presacral with sacral involvement, pelvic nodules, liver, right iliac bone); no spinal canal compromise documented. [@2022-12-29|MR; @2022-12-29|CT]\n\n- Given clear anatomic progression on CT/MR, PET‑CT may be deferred unless needed for focal local therapy or trial eligibility. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\n- Recommend interval imaging follow‑up focusing on sacrum/iliac bone for impending fracture or neural compromise risk assessment. [@2022-12-29|MR]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm ECOG, full labs, and symptom burden to judge feasibility of further systemic therapy versus purely supportive care.[@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\n- Complete biomarker panel: MSI (to confirm MMR proficiency), PD‑L1, TMB, and updated tumor NGS including somatic ATM status.[@report_id|2022-03-28][@report_id:OH2203828|2022-04-18]\n\n- Consider PET‑CT only if results would influence focal local therapy or trial eligibility, not for basic staging clarification.[@guideline:nccn_ovariancancer_v3_2025__v00000000|15]&quot;,
    &quot;nuclear&quot;: &quot;- Current MR/CT already confirm multifocal progression (pelvis/presacral, liver, bone); PET-CT not yet performed so metabolic extent remains unknown/needs update [@2022-12-29|MR; @2022-12-29|CT].  \n\n- PET-CT is unlikely to change overall staging but may assist if considering focal radiotherapy/surgery or trial eligibility requiring metabolic documentation [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- If new neurologic symptoms or concern for sacral canal compromise arise, targeted MRI or PET-MR rather than whole-body PET-CT should be prioritized [@2022-12-29|MR].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>2</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>2</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>2</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Metastatic ovarian clear cell carcinoma with prior platinum-based chemo ending &lt;6 months (platinum-resistant); liver, pelvic/peritoneal, bone, rectal involvement; MMR-proficient (MLH1/MSH2/MSH6/PMS2+); ER/PR low-positive; need guidance on systemic options and local control; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6667 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…
[2] score=0.6647 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]
    n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D). dd Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Tumor molecular analysis is recommended to include, at a minimum, tests to identify potent…
[3] score=0.6581 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]
    n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D). dd Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Tumor molecular analysis is recommended to include, at a minimum, tests to identify potent…
[4] score=0.6561 nccn_ovariancancer_v3_2025__v00000000 [PAGE 22] [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]
    Survivorship) Recurrent diseaset Hormonal therapyu or Chemotherapy (if not previously used), see OV-C (6 of 12) or Systemic therapyf,v • For platinum-sensitive disease, see OV-C (8 of 12) • For platinum-resistant disease, see OV-C (9 of 12) or Observation f See Principles of Systemic Therapy (OV-C) …
[5] score=0.6504 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7000 PMID 33758607 [@pubmed:33758607]
    Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
    Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometr…
[2] score=0.6973 PMID 36591227 [@pubmed:36591227]
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.
    Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radi…
[3] score=0.6731 PMID 37901720 [@pubmed:37901720]
    Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.
    Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common.            In our hospital, we recently summa…
[4] score=0.6717 PMID 36439155 [@pubmed:36439155]
    Case report: Local cryoablation combined with pembrolizumab to eliminate lung metastases from ovarian clear cell carcinoma.
    Ovarian clear cell carcinoma has a high recurrence rate with poor prognosis and is generally not sensitive to conventional platinum-based chemotherapy. Its less frequent occurrence of mutations such as BRCA limited the targeted therapies. Immunotherapy is not currently recommended as a first-line ag…
[5] score=0.6715 PMID 33490225 [@pubmed:33490225]
    Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.
    Malignant ovarian germ cell tumours (MOGCTs) are rare. Unlike epithelial ovarian cancer, MOGCTs typically occur in girls and young women. Fertility-sparing surgery and platinum-based chemotherapy remain the standard of care, providing high chance of cure at all stages. Given the lack of high-quality…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6666727066040039,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6647226810455322,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6581206917762756,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using\nthe most recent available tumor tissue. Tumor molecular analysis is recommended to\ninclude, at a minimum, tests to identify potential benefit from targeted therapeutics that\nhave tumor-specific or tumor-agnostic benefit including, but not limited to, HER2 status\n(by IHC), BRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and\nNTRK if prior testing did not include these markers. More comprehensive testing may be\nparticularly important in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if\nnot previously done.\nBest supportive care (See NCCN Guidelines for Palliative Care)\nand/or\nRecurrence therapy (OV-C, 9 of 12)n,jj,kk\nTHERAPY FOR PERSISTENT DISEASE OR RECURRENCEn,gg,hh,ii\nff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6561352610588074,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 22,
    &quot;text&quot;: &quot;Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\n• For platinum-sensitive disease, see OV-C (8 of 12)\n• For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRα (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.650352954864502,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.699963030510074,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33758607&quot;,
    &quot;title&quot;: &quot;Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrioid carcinoma, which also originates from endometriosis, shares several features with OCCC, including platinum resistance and younger age at diagnosis. Patients with OCCC have about a 2.5 to 4 times greater risk of having a venous thromboembolism (VTE) compared with other EOC, and OCCC tends to metastasize through lymphatic vesicular and peritoneal spread as opposed to hematogenous metastasis. There is only mild elevation of the conventional biomarker CA125. Staging surgery or optimal cytoreduction combined with chemotherapy is a common therapeutic strategy for OCCC. However, platinum resistance commonly portends a poor prognosis, so novel treatments are urgently needed. Targeted therapy and immunotherapy are currently being studied, including PARP, EZH2, and ATR inhibitors combined with the synthetic lethality of ARID1A-dificiency, and MAPK/PI3K/HER2, VEGF/bFGF/PDGF, HNF1β, and PD-1/PD-L1 inhibitors. Advanced stage, suboptimal cytoreduction, platinum resistance, lymph node metastasis, and VTE are major prognostic predictors for OCCC. We focus on update pathogenesis, diagnostic methods and therapeutic approaches to provide future directions for clinical diagnosis and treatment of OCCC.&quot;,
    &quot;journal&quot;: &quot;J Cancer&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.7150/jca.53395&quot;,
    &quot;impact_factor&quot;: 3.2,
    &quot;similarity&quot;: 0.699963030510074
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6972808900187843,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36591227&quot;,
    &quot;title&quot;: &quot;Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radiotherapy and a few cycles of chemotherapy with an extremely durable response even after cessation of immunotherapy for 3 years at the time of publication.&quot;,
    &quot;journal&quot;: &quot;Front Immunol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fimmu.2022.1079253&quot;,
    &quot;impact_factor&quot;: 5.9,
    &quot;similarity&quot;: 0.6972808900187843
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6730853434243357,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;37901720&quot;,
    &quot;title&quot;: &quot;Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.&quot;,
    &quot;abstract&quot;: &quot;Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common.\n          \nIn our hospital, we recently summarized two patients with ovarian clear cell carcinoma with similar characteristics. They all had endometriosis for a long time and had undergone ovarian cyst removal due to a chocolate cyst. Unfortunately, the cyst recurred after surgery, and the histological diagnosis was clear cell carcinoma. In case 1, the expression of P53 was found in the tumor by regular examination, and the stage was IIB. In Case 2, we found it in intraoperative freezing; the stage was IA. Case 1 has been treated with the TP regimen six times, and the survival period has reached one year. Case 2 had a survival period of 6 years after completing six TP regimen treatments. Clinicians should pay attention to patients with a long history of endometriosis and postoperative recurrence of ovarian cysts accompanied by serum CA-125 of more than 200U/mL. Imaging examination has a good prospect in diagnosing malignant transformation of endometriosis, especially PET-CT.\n          \nThis case report highlights the risk factors related to the formation of ovarian clear cell carcinoma and suggests that the follow-up of patients with ovarian endometriosis is essential because of its recurrence characteristics. Radical surgery and postoperative platinum-containing chemotherapy are the primary treatment methods at present.&quot;,
    &quot;journal&quot;: &quot;Int J Womens Health&quot;,
    &quot;pub_date&quot;: &quot;2023-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/IJWH.S418135&quot;,
    &quot;impact_factor&quot;: 2.6,
    &quot;similarity&quot;: 0.6730853434243357
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6716572713762173,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36439155&quot;,
    &quot;title&quot;: &quot;Case report: Local cryoablation combined with pembrolizumab to eliminate lung metastases from ovarian clear cell carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma has a high recurrence rate with poor prognosis and is generally not sensitive to conventional platinum-based chemotherapy. Its less frequent occurrence of mutations such as BRCA limited the targeted therapies. Immunotherapy is not currently recommended as a first-line agent for ovarian cancer, and most patients are not yet able to benefit from it. Cryoablation can be used to treat solid systemic tumors, including ovarian cancer metastases, and can produce a limited anti-tumor immune response. The anti-tumor effects of cryoablation combined with immunotherapy have not been adequately confirmed. This study reports a case of a patient with ovarian clear cell carcinoma who underwent conventional adjuvant chemotherapy after initially surgical resection of the tumor. Unfortunately, cancer recurred and metastasized to the abdominal wall. After a series of painful chemotherapy and a second surgery, the cancer was still not effectively controlled, and the patient developed extensive metastases in the lung. The patient&#x27;s PD-L1 expression level also did not support solo immunotherapy. We pioneered the use of cryoablation to first eradicate the most significant lesion in the upper lobe of the left lung and then combined it with the PD-L1 inhibitor pembrolizumab to treat the patient with immunotherapy, which resulted in the complete eradication of the other multiple metastases in the lung and saved the patient&#x27;s life. Although the precise mechanism of action has not yet been explored, we have reason to believe that the combination of cryoablation and immune checkpoint inhibitor has a powerful synergistic anti-tumor effect, which is yet to be confirmed by more basic research and clinical applications in the next step.&quot;,
    &quot;journal&quot;: &quot;Front Immunol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fimmu.2022.1006500&quot;,
    &quot;impact_factor&quot;: 5.9,
    &quot;similarity&quot;: 0.6716572713762173
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6715012700025748,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33490225&quot;,
    &quot;title&quot;: &quot;Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.&quot;,
    &quot;abstract&quot;: &quot;Malignant ovarian germ cell tumours (MOGCTs) are rare. Unlike epithelial ovarian cancer, MOGCTs typically occur in girls and young women. Fertility-sparing surgery and platinum-based chemotherapy remain the standard of care, providing high chance of cure at all stages. Given the lack of high-quality studies in this field, current practice guidelines recommend chemotherapy regimens adopted in testicular germ cell tumours. However, platinum-resistant/refractory MOGCTs retain a worse prognosis in comparison with their male counterpart. Herein, we focus on current systemic anti-cancer treatment options in MOGCTs and promising approaches. Future studies enrolling exclusively female participants or germ cell tumour trials allowing participation of MOGCT patients are strongly recommended in order to improve evidence on existing management and develop novel strategies.&quot;,
    &quot;journal&quot;: &quot;Ann Transl Med&quot;,
    &quot;pub_date&quot;: &quot;2020-12-01&quot;,
    &quot;doi&quot;: &quot;10.21037/atm.2020.04.15&quot;,
    &quot;impact_factor&quot;: 3.616,
    &quot;similarity&quot;: 0.6715012700025748
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- Platinum-sensitive vs platinum-resistant ovarian cancer represents a clinical spectrum; treatment choice (e.g., chemotherapy, targeted agents, observation) should be individualized rather than based on rigid cutoffs. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]

- Comprehensive tumor molecular profiling (in a CLIA-approved lab) is recommended at recurrence to identify actionable alterations (eg, BRCA/HRR, MSI-H/dMMR, TMB-H, NTRK fusions, others) to guide systemic therapy and trial eligibility. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]

- For recurrent ovarian cancer, systemic therapy selection should incorporate validated molecular testing results along with platinum sensitivity status; targeted or immunotherapy approaches may be appropriate in biomarker-selected populations. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]

- For recurrent disease, options include hormonal therapy, chemotherapy (if not previously used), or other systemic therapy; platinum-sensitive and platinum-resistant disease are managed via different systemic therapy pathways, with observation also acceptable in selected cases. [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]

- At first recurrence, platinum-based combination chemotherapy is preferred (category 1) in appropriate candidates; consider secondary cytoreductive surgery and/or best supportive care, with immediate platinum-based recurrence therapy as a category 2B option in selected scenarios. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]

- Ovarian clear cell carcinoma (OCCC) is relatively chemoresistant, frequently associated with endometriosis, and has distinct molecular features (e.g., ARID1A, PIK3CA mutations), supporting consideration of non-platinum strategies and clinical trials targeting PI3K/AKT/mTOR, angiogenesis, and immune pathways. [@pubmed:33758607]

- Clear cell histology (including endometrial CCC) tends to be platinum-refractory; case-level evidence suggests pembrolizumab, sometimes combined with radiotherapy to induce an abscopal effect, can produce durable responses, supporting MDT consideration of immune checkpoint blockade in selected biomarker-appropriate patients. [@pubmed:36591227]

- Endometriosis-associated ovarian cancer, particularly clear cell carcinoma, is uncommon but important; recurrent disease may arise from persistent or recurrent endometriosis, underscoring the need for vigilant imaging and pathologic assessment of new endometriotic lesions in follow-up. [@pubmed:37901720]

- Case report data indicate that local ablative therapies (e.g., cryoablation of metastases) combined with pembrolizumab can achieve meaningful responses in metastatic OCCC, suggesting a role for consolidative local therapy plus immunotherapy in oligometastatic or resistant disease when standard options are limited. [@pubmed:36439155]

- Malignant ovarian germ cell tumors differ from epithelial tumors; standard management is fertility-sparing surgery plus platinum-based chemotherapy, with high cure rates, so MDT decisions must distinguish germ cell from epithelial histologies to avoid overtreatment and to prioritize curative, fertility-preserving approaches. [@pubmed:33490225]</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Guideline+PubMed RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-19T08:36:31.278474&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:36:31.278813&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;efe856c0897d&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:36:31.592684&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:36:40.150427&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:36:40.157675&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=卵巢癌复发; histology=首先考虑为透明细胞癌; components=高级别腺癌\nPATHOLOGY: 部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\nPLATINUM: status=Resistant; pfi_days=56\nGENETICS: HRD=Unknown; BRCA1=Unknown; BRCA2=Unknown\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; note=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PAL…&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:13.539633&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Metastatic ovarian clear cell carcinoma with prior platinum-based chemo ending &lt;6 months (platinum-resistant); liver, pelvic/peritoneal, bone, rectal involvement; MMR-proficient (MLH1/MSH2/MSH6/PMS2+); ER/PR low-positive; need guidance on systemic options and local control; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:13.539657&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:13.539659&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:13.539661&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:22.143523&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:22.143586&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:25.097513&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 567
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:25.097636&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:27.758507&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 551
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:27.758576&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:29.999527&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 492
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:29.999646&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:32.305176&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 526
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:32.305244&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:37:34.667463&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 535
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:39:05.242394&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2531
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:39:05.244953&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:39:08.074233&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:39:08.074256&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:39:39.581949&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1487
    }
  }
]</pre>
  </details>

</body>
</html>
